Altre lingue Ardelyx, Inc.

Azioni

ARDX

US0396971071

Tempo reale stimato Cboe BZX Altri mercati azionari 16:58:20 16/07/2024			Variaz. 5gg	Var. 1 gen.
6,025 ^USD	+1,26%		+8,36%	-2,82%

02/07	Aggiornamento settoriale: i titoli del settore sanitario sono in ribasso martedì prima del mercato	MT
02/07	Ardelyx rinuncia all'adeguamento del pagamento CMS per Xphozah; le azioni crollano prima della campanella	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

ARDX Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Ardelyx, Inc. for Potential Securities Law Violations	02/07
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	02/07
Ardelyx Opts Out of CMS Payment Adjustment for Xphozah; Shares Plunge Pre-Bell	02/07
Sector Update: Health Care	02/07
Ardelyx Opts Out of CMS Payment Adjustment for Xphozah	02/07
Ardelyx Chose Not To Apply To Include Xphozah In CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment	02/07
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA	02/07
Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH	02/07
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 2000 Value Index	01/07
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 3000 Value Index	01/07
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 2500 Value Index	01/07
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index	01/07
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 3000E Value Index	01/07
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines	28/06
Ardelyx, Inc. Reports Employment Inducement Grants	30/05
Ardelyx Shares Fall; Chief Commercial Officer Resigns	24/05
Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer	23/05
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference	22/05
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults	21/05
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)	16/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ardelyx, Inc.

Azioni

ARDX

US0396971071

Altre lingue

Filtri